7AMP
| Crystal structure of the complex of HuJovi-1 Fab with the human A6 T-cell receptor TRBC1 | Descriptor: | Alpha chain of A6 T-cell receptor, Beta chain 1 of A6 T-cell receptor TRBC1, CHLORIDE ION, ... | Authors: | Ferrari, M, Bulek, A, Bughda, R, Jha, R, Welin, M, Logan, D.T, Sewell, A, Onuoha, S, Pule, M. | Deposit date: | 2020-10-09 | Release date: | 2022-04-20 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (2.64 Å) | Cite: | Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies Res Sq, 2022
|
|
7AMQ
| Crystal structure of the complex of HuJovi-1 Fab with the human TRBC2 | Descriptor: | CHLORIDE ION, GLYCEROL, Human A6 T-cell receptor alpha chain, ... | Authors: | Ferrari, M, Bulek, A, Bughda, R, Jha, R, Welin, M, Logan, D.T, Sewell, A, Onuoha, S, Pule, M. | Deposit date: | 2020-10-09 | Release date: | 2022-04-20 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.353 Å) | Cite: | Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies Res Sq, 2022
|
|
7AMS
| Crystal structure of the complex of the KFN mutant of HuJovi-1 Fab with human TRBC2 | Descriptor: | CHLORIDE ION, GLYCEROL, Human A6 T-cell receptor alpha chain, ... | Authors: | Ferrari, M, Bulek, A, Bughda, R, Jha, R, Welin, M, Svensson, A, Logan, D.T, Sewell, A, Onuoha, S, Pule, M. | Deposit date: | 2020-10-09 | Release date: | 2022-04-20 | Last modified: | 2022-04-27 | Method: | X-RAY DIFFRACTION (2.419 Å) | Cite: | Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies Res Sq, 2022
|
|
7AMR
| Crystal structure of the complex of the KFN mutant of Jovi-1 Fab with human TRBC1 | Descriptor: | CHLORIDE ION, GLYCEROL, Human Jovi-1 Fab fragment, ... | Authors: | Ferrari, M, Bulek, A, Bughda, R, Jha, R, Welin, M, Logan, D.T, Sewell, A, Onuoha, S, Pule, M. | Deposit date: | 2020-10-09 | Release date: | 2022-04-20 | Last modified: | 2022-04-27 | Method: | X-RAY DIFFRACTION (1.949 Å) | Cite: | Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies Res Sq, 2022
|
|